• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Regeneron Pharmaceuticals - Articles and news items

high-cholesterol

Success for Sanofi and Regeneron’s LDL cholesterol trial

Industry news / 30 August 2016 / Niamh Louise Marriott, Digital Content Producer

The trial showed adding praluent to existing therapy reduced LDL cholesterol by approximately 50% from baseline, compared to 2% increase for placebo…

cimzia arthritis x-ray hands bones

Sanofi and Regeneron announce EMA acceptance for review of Marketing Authorisation Application for sarilumab

Industry news / 1 August 2016 / Sanofi / Regeneron Pharmaceuticals, Inc.

Sanofi and Regeneron Pharmaceuticals, Inc. have announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for sarilumab, an investigational human monoclonal antibody directed against the IL-6 receptor that is intended for the treatment of adult patients with moderately to severely active rheumatoid arthritis…

Dupilumab

Dupilumab + TCS superior to TCS alone in treating atopic dermatitis

Industry news / 6 June 2016 / Victoria White, Digital Content Producer

Sanofi and Regeneron have announced that a Phase III study evaluating dupilumab in atopic dermatitis met its primary and key secondary endpoints…

dupilumab

Positive topline results from two Phase III dupilumab studies

Industry news / 1 April 2016 / Victoria White

The two Phase III studies evaluated investigational dupilumab in adult patients with inadequately controlled moderate-to-severe atopic dermatitis…

regeneron and bayer

Regeneron and Bayer team up to develop a novel therapy for eye diseases

Industry news / 24 March 2016 / Victoria White

Regeneron and Bayer are to develop a combination therapy of the Ang2 antibody nesvacumab and the VEGF trap aflibercept for the treatment of eye diseases…

apheresis

Positive results for Praluent in patients undergoing LDL apheresis therapy

Industry news / 23 March 2016 / Victoria White

Patients who added Praluent to their existing treatment regimen significantly reduced the frequency of their apheresis therapy by 75% compared to placebo….

Sanofi and Regeneron

Amgen wins drug patent case against Sanofi and Regeneron

Industry news / 17 March 2016 / Victoria White

A jury has delivered a verdict in Amgen’s favour in a trial on the validity of two Amgen patents that describe and claim monoclonal antibodies to PCSK9…

Sarilumab

sarilumab demonstrates superiority to adalimumab in rheumatoid arthritis

Industry news / 11 March 2016 / Victoria White

A Phase III study demonstrated that sarilumab was superior to adalimumab in improving signs and symptoms in patients with active RA…

alirocumab

NICE says ‘no’ to alirocumab in draft guidance

Industry news / 8 February 2016 / Victoria White

NICE was concerned that alirocumab had not been compared with the combination therapy of ezetimibe plus a statin and that trials of the drug were not able to provide robust information on cardiovascular outcomes…

eylea

EC approves Eylea for myopic choroidal neovascularisation

Industry news / 30 October 2015 / Victoria White

Bayer plans for an immediate introduction of Eylea to the market with Germany being one of the first launch countries in Europe…

praluent

EC approves LDL cholesterol treatment Praluent

Industry news / 28 September 2015 / Victoria White

Praluent is the only EC-approved PCSK9 inhibitor that is available in two starting doses, offering two levels of efficacy…

praluent

FDA approves Praluent for the treatment of high LDL cholesterol

Industry news / 26 August 2015 / Victoria White

The US Food and Drug Administration (FDA) has approved Praluent (alirocumab) Injection – the first and only PCSK9 inhibitor approved in the US…

 

Win an Amazon Gift Card worth up to €100!TAKE OUR SURVEY
+ +